Company Overview of Zynerba Pharmaceuticals, Inc.
Zynerba Pharmaceuticals, Inc., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates include ZYN002, which is in Phase II clinical trial for adult patients with refractory epileptic focal seizures and osteoarthritis, as well as pediatric patients with fragile X syndrome; and ZYN001 that is in preclinical stage for the treatment of fibromyalgia and peripheral neuropathic pain. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was founded in 2007 and is...
80 West Lancaster Avenue
Devon, PA 19333
Founded in 2007
Key Executives for Zynerba Pharmaceuticals, Inc.
Chairman and Chief Executive Officer
Total Annual Compensation: $873.0K
Total Annual Compensation: $668.5K
Chief Financial Officer and Vice President of Corporate Development
Total Annual Compensation: $248.1K
Vice President of Human Resources, General Counsel and Secretary
Total Annual Compensation: $317.5K
Compensation as of Fiscal Year 2016.
Zynerba Pharmaceuticals, Inc. Key Developments
Zynerba Pharmaceuticals, Inc. Announces Enrollment Target of 16 Patients in Phase 2 FAB-C (Treatment of Fragile X Syndrome Anxiety and Behavioral Challenges with CBD) Clinical Trial Evaluating ZYN002 Cannabidiol (CBD) Gel in Children with Fragile X Syndrome
Jun 8 17
Zynerba Pharmaceuticals, Inc. announced that it has met its enrollment target of 16 patients in its Phase 2 FAB-C (Treatment of Fragile X Syndrome Anxiety and Behavioral Challenges with CBD) clinical trial evaluating ZYN002 cannabidiol (CBD) gel in children with Fragile X syndrome (FXS). ZYN002 CBD gel is the first and only patent-protected, synthetic CBD that is formulated as a permeation-enhanced gel for transdermal delivery, and was awarded orphan drug designation by the U.S. Food and Drug Administration for the treatment for FXS. Patients between the ages of 6 and 17 years with Fragile X syndrome have been enrolled in the exploratory FAB-C trial, which is designed to evaluate the safety and efficacy of ZYN002 CBD gel administered over a 12-week period in FXS. The study is evaluating 50 mg of CBD in ZYN002 4.2% gel once daily, which may be titrated up to 125 mg two times per day during the six-week titration period. Between weeks six and twelve, patients will receive a maintenance dose of 50 mg, 100 mg or 250 mg daily of CBD in ZYN002 4.2% gel. The primary outcome measures include changes in anxiety, depression and mood as measured by the ADAMS scale, a patient reported outcomes questionnaire that has been validated in FXS. Other measurements that are being observed include the Aberrant Behavior Checklist and visual analog scale (VAS) to assess for hyperactivity/impulsivity. Fragile X syndrome is an autism spectrum disorder and the most common inherited intellectual disability in males and a significant cause of intellectual disability in females. It is caused by a mutation in the Fragile X Mental Retardation gene located on the X chromosome and leads to dysregulation of the endocannabinoid pathway including the reduction in endogenous cannabinoids (2-AG and anandamide). The disorder negatively affects synaptic function, plasticity and neuronal connections, and results in a spectrum of intellectual disabilities, social anxiety and memory problems. In the US, there are about 71,000 patients suffering with FXS.
Zynerba Pharmaceuticals, Inc. Presents at Jefferies 2017 Global Healthcare Conference, Jun-08-2017 01:30 PM
Jun 1 17
Zynerba Pharmaceuticals, Inc. Presents at Jefferies 2017 Global Healthcare Conference, Jun-08-2017 01:30 PM. Venue: Grand Hyatt, 109 E 42nd St, New York, New York, United States. Speakers: James E. Fickenscher, Chief Financial Officer and Vice President of Corporate Development.
Zynerba Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for First Quarter Ended March 31, 2017
May 9 17
Zynerba Pharmaceuticals, Inc. announced unaudited consolidated earnings results for first quarter ended March 31, 2017. For the quarter, the company reported loss from operations of $7,703,248,000, loss before income taxes of $7,259,021,000, net loss of $7,259,021,000, net loss per share - basic and diluted of $0.6,000 compared to the loss from operations of $4,241,869,000, loss before income taxes of $4,252,640,000, net loss of $4,281,374,000, net loss per share - basic and diluted of $0.49,000 for the same quarter a year ago.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|